[First trimester screening for Down syndrome: five years prospective experience].
First trimester screening for Down syndrome is yet to become the first intention strategy in France. This screening program at 11-14 weeks of gestation using maternal age, fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A has already been validated for a long time by many international studies. It seems to improve detection rate and decrease false positive rates. We report here five years prospective experience.
Weingertner
A-S
AS
Pôle de gynécologie obstétrique, département d'échographie et de diagnostic anténatal, centre médicochirurgical et obstétrical SIHCUS, 19, rue Louis-Pasteur, 67303 Schiltigheim cedex, France. Anne-Sophie.Weingertner@sihcus.fr
Trieu
N-T
NT
Kohler
M
M
Viville
B
B
Levy
G
G
Montaya
Y
Y
Kutnahorsky
R
R
Tissier
I
I
Kohler
A
A
Tanghe
M
M
Mager
C
C
Benassi
E
E
Cancelier
M
M
Neuman
M
M
Bouffet
N
N
Hunsinger
M C
MC
Hornecker
F
F
Langer
B
B
Nisand
I
I
Favre
R
R
D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D004314:Down Syndrome / Q000175:diagnosis*; D005189:False Positive Reactions; D005260:Female; D005865:Gestational Age; D006801:Humans; D008423:Maternal Age; D015337:Multicenter Studies as Topic; D048208:Nuchal Translucency Measurement; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis; D011296:Prenatal Diagnosis; D011446:Prospective Studies
D018997:Chorionic Gonadotropin, beta Subunit, Human; D011266:Pregnancy-Associated Plasma Protein-A